A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
- Study HIC#:2000038520
- Last Updated:02/13/2025
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted gastrointestinal, biliary tract, or pancreatic cancers.
Contact Us
For more information about this study, including how to volunteer, contact:
Katie Wildman
- Phone Number: 1-203-615-2783
Help Us Discover!
You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call +18779788343 for more information.
Eligibility Criteria
Inclusion Criteria
- Subprotocol B Inclusion: - Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years). - Histologically or cytologically confirmed diagnosis of metastatic and/or unresectable (locally advanced) adenocarcinoma of the pancreas. - Tumor tissue (FFPE sample) or an archival block must be available. Participants without archived tumor tissue available may be allowed to enroll by undergoing tumor biopsy before dosing. - Homozygous MTAP-deletion. - Disease measurable as defined by RECIST v1.1. - Adequate organ function as defined in the protocol. Exclusion: - Prior treatment with a MAT2A inhibitor or a PRMT5 inhibitor. - Radiation therapy within 28 days of first dose. - Major surgery within 28 days of first dose of AMG 193. - Cardiovascular and pulmonary exclusion criteria as defined in the protocol. - Gastrointestinal tract disease causing the inability to take PO medication, malabsorption syndrome, requirement for IV alimentation, gastric/jejunal tube feeds, uncontrolled inflammatory gastrointestinal disease (eg, Crohn's disease, ulcerative colitis). - History of solid organ transplantation.
